Key facts
- OncoResponse’s last known valuation is $36.0M (May 2023).
- It has raised $180.0M across 2 recorded rounds; the latest was Early Stage VC ($6.0M) in Apr 2025.
- Notable investors include Alexandria Venture Investments, Canaan Partners, InterVest, ARCH Venture Partners, Qatar Investment Authority — 25 tracked in total.
- OncoResponse has filed 2 Form Ds with the SEC since 2018, most recently May 2025 ($6.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for OncoResponse
Funding rounds
2 roundsAbout OncoResponse
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. The company leverages a proprietary B-cell technology platform to develop cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system, helping doctors and patients to combat cancer optimally.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2015
- Employees
- 11
- Website
- oncoresponse.com/
- Ownership
- Privately Held (backing)
OncoResponse doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoResponse shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoResponse in its N-PORT filings yet. We sweep new filings monthly.